Oslo, Norway, November 15, 2011: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces today that its Chief Financial Officer (CFO), Christian Fekete, has resigned.
Christian Fekete has served as CFO in Photocure since November 2004. He is looking to explore new opportunities outside Photocure. He will leave the company on December 1st, 2011. The company will initiate the search to identify a new CFO.
Kjetil Hestdal, President & CEO of Photocure, said:
“We would like to thank Christian Fekete for his long and great contribution as CFO in Photocure. We wish him all the best for the future.”
For further information, please contact:
President & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email: email@example.com
Tel: +44 207920 2361, Email: firstname.lastname@example.org
About Photocure ASA
Photocure ASA is a worldwide leader in photodynamic technology. Listed on the Oslo Stock Exchange (OSE: PHO), Photocure is focused on photodynamic technologies in dermatology and cancer. The company strives to solve unmet needs by developing new and innovative solutions based on its patented Photocure Technology™. Photocure markets and sells its own products in selected markets and has developed strong partnerships with leading pharmaceutical companies on a regional and global basis. Photocure’s bladder cancer diagnostic product, Hexvix is approved in Europe and the US. In addition, the company markets Allumera®, a photodynamic cosmetic in the US. Setting new standards for diagnosis and treatment of several different conditions, Photocure Technology™ is continuously being tested for new products and applications in cancer and dermatology.
Allumera®, Photocure® and Hexvix® are registered trademarks of Photocure ASA. For more information about Photocure, visit www.photocure.com.